http://www.fpnotebook.com/
NaproxenAka: Naprosyn, Anaprox, Aleve
- Class
- NSAID in the propionic acid class
- Pharmacokinetics
- Naproxen sodium has faster action onset than Naproxen
- Dosing
- Naproxen (Naprosyn) 250-500 mg PO bid prn
- Naproxen Sodium (Anaprox, Aleve) 550 mg PO bid prn
- Adverse Effects
- See NSAID Gastrointestinal Adverse Effects
- See NSAID Renal Adverse Effects
- Bleeding risk (inhibits platelet aggregation)
- Naprosyn increases risk almost as much as Aspirin
|
|---|
| Definition (MSH) | An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. |
| Definition (CSP) | 6-methoxy-alpha-methyl-2-naphthaleneacetic acid; nonsteroidal antiinflammatory drug (NSAID); acts by inhibiting cyclooxygenase and thus prostaglandin synthesis; tocolytic oxytocin antagonist. |
| Definition (PDQ) | A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40222&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40222&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C680" NCI Thesaurus) |
| Definition (NCI) | A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. |
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | Methoxypropiocin, MNPA, Naproxen, NAPROXEN PREPARATION, Naproxen product |
| Spanish | naproxeno |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
|
|---|
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | Naprosin, Naprosyn |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree
